This patient has cyanotic congenital heart disease with Eisenmenger syndrome. Patients with Eisenmenger syndrome usually have hemoglobin levels of 18-20 g/dL and a hematocrit level > 65%. In this patient, the level is markedly reduced since she has cyanotic congenital heart disease. Her decrease in hemoglobin/hematocrit is most likely associated with menorrhagia, and her resulted in fatigue and exertional dyspnea due to reduced oxygen-carrying capacity being that she is cyanotic. The treatment of choice, unless volume-depleted, would be low-dose iron therapy (325mg/day) for 7-10 days and a re-evaluation of her Hb/Hct afterwards. If they have increased, iron therapy should be discontinued.
Blood transfusion is required if the hemoglobin level is less than 10 g/dL, has severe symptoms related to the anemia, in the presence of excessive bleeding, or at the time of surgery and expected blood loss.
Treatment options for patients with this syndrome include lung transplantation with intracardiac repair and pulmonary vasodilator therapy. Pulmonary vasodilators can improve symptoms, but would not be the treatment of choice in this patient until the hemoglobin is corrected. If symptoms persist after correcting the anemia, then pulmonary vasodilators may benefit this patient. Another option would be heart-lung transplantation.
Observation and follow-up is not appropriate.
Key Point
In a patient with Eisenmenger Syndrome and anemia, the treatment of choice is low dose iron therapy and reassessment of the Hb/Hct after 7-10 days.
Reference: ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease.
Recent Comments